Occlutech clarifies statement regarding favourable opinion obtained from AIPPI with regard to patents held by AGA Medical

Jena (Germany) 17 April (PROTEXT/ots) - Occlutech GmbH, the leadingEuropean manufacturer of cardiac occlusion devices today announced aclarification of a recent news release.

In a news release dated February 8th, 2008, Occlutech stated that itreceived an opinion from AIPPI the European "Association for the Protectionof Intellectual Property" with regard to non infringement by Occlutech ofcertain European IP held by AGA Medical.

AIPPI has requested a clarification of this statement:

1) The name European International Association for the Protection ofIntellectual Property was not stated correctly. The correct name is the"International Association for the Protection of Intellectual Property".

2) The opinion received by Occlutech which states that Occlutech is notinfringing EP 0808138B1 and its Italian part 019020BE/2006 held by AGAMedical Corp was commissioned through the Italian National Group of AIPPIbut not issued by AIPPI International itself. The opinion was issued by andin the name of three independent experts nominated by the Italian Group ofAIPPI. The opinion was issued by the experts nominated by the ItalianBranch of AIPPI and not by, in the name of or on behalf of AIPPIInternational or the Italian National Group of AIPPI.

The opinion was given without influence of Occlutech GmbH and theimpartiality of the experts has subsequently been confirmed by the ItalianBranch of AIPPI.

3) Such an independent opinion commissioned through AIPPI is an instrumentaiming at giving the requiring party a qualified and impartial opinion. Itdoes not represent an official opinion by AIPPI since AIPPI does not getinvolved in intellectual property disputes between parties on behalf or infavour of one of the parties.

Occlutech GmbH regrets that its communication was not clear with regard tothe role of AIPPI in commissioning and receiving the opinion.

Occlutech GmbH develops and manufactures a wide range of occluders that aresold under the Occlutech Figulla N brand in over 40 countries in Europeanand international markets. Clinical programs leading to regulatory approvalin the US and Japan are underway.

Contact:

Robert Moszner

E-mail: robert.moszner@occlutech.com

Phone: +49-3641 67 51 20

Susanne Goransson

E-mail: info@occlutech.info

Phone: +46-704336521

Subscribers please note that material bearing the label "PROTEXT" is notpart of CTK's news service and is not to be published under the "CTK"label. Protext is a commercial service providing distribution of pressreleases from clients, who are identified in the text of Protext reportsand who bear full responsibility for their contents.

PROTEXT